Attached files

file filename
10-Q - 10-Q - Zentalis Pharmaceuticals, Inc.zntl-20200630.htm
EX-32.1 - EX-32.1 - Zentalis Pharmaceuticals, Inc.zentalis10-qq22020exhi.htm
EX-31.2 - EX-31.2 - Zentalis Pharmaceuticals, Inc.zentalis10-qq22020exhi2.htm
EX-31.1 - EX-31.1 - Zentalis Pharmaceuticals, Inc.zentalis10-qq22020exhi3.htm
EX-10.3 - EX-10.3 - Zentalis Pharmaceuticals, Inc.zentalis10-qq22020exhibi.htm
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc. (the “Company”) for the period ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 13, 2020
By:/s/ Melissa B. Epperly
Melissa B. Epperly
Chief Financial Officer
(principal financial officer)